Biochemical & Body Fluid Analysis Service

Comprehensive monitoring of drug effects on systemic physiology and metabolism is fundamental to safety pharmacology and toxicology studies. Leveraging its preclinical diagnostic platform, Alfa Cytology offers integrated blood and body fluid analysis services to quantitatively and dynamically evaluate the impact of drug candidates on hematopoietic, hepatic, renal, coagulation, and metabolic functions in laboratory animals. This comprehensive suite fully supports preclinical toxicology evaluation for oncology drug development.

Introduction to Biochemical & Body Fluid Analysis

The systemic toxicities of anticancer agents represent a key factor limiting their clinical utility. Myelosuppression-induced cytopenia is the most common dose-limiting toxicity of chemotherapeutic drugs; elevated liver enzymes and renal impairment signal potential damage to metabolic and excretory organs; and coagulation abnormalities may predict thrombotic or hemorrhagic risks. Blood and body fluid analysis provides a rapid, sensitive, and quantifiable means to dynamically monitor drug-induced changes in hematopoietic function, hepatorenal function, electrolyte balance, and coagulation status in animal models, delivering indispensable clinical pathology data to inform dose optimization and safety evaluation.

Fig. 1 Leukemias and their detection by the complete blood count (CBC). (Gonzaga Y, et al.; 2025)

Our Services

Alfa Cytology offers a comprehensive suite of biochemical and body fluid analysis services designed to assess the systemic physiological impact of cancer therapies on hematopoietic function, organ metabolism, and hemostatic balance. Our platform integrates complete blood count (CBC), serum biochemistry, urinalysis, and coagulation panel testing to deliver multidimensional clinical pathology data. Whether you are evaluating myelosuppression risk, monitoring hepatorenal function, assessing coagulation disorders, or characterizing metabolic changes, our services provide the critical clinical pathology evidence needed to support confident go/no-go decisions and regulatory submissions.

Test Types

Supported Therapeutic Modalities

Our biochemical and body fluid analysis services broadly support the research and development of diverse cancer therapeutic modalities. By systematically evaluating the impact of drug candidates on the hematopoietic system, hepatic and renal function, hemostatic balance, and multi-system fluid homeostasis, we provide critical clinical pathology data to underpin preclinical safety assessment and toxicology studies across a wide range of therapeutic approaches.

Small Molecule	Therapeutic Antibody	Cell Therapy	Gene Therapy
Cancer Vaccine	Peptide Therapy	Nucleic Acid Therapeutics	Oncolytic Viral Therapy

Applicable Samples and Species

Applications of Our Biochemical & Body Fluid Analysis Service

Myelosuppression Assessment

Myelosuppression is a common dose-limiting toxicity of chemotherapeutics. Serial CBC monitoring enables quantitative evaluation of drug effects on erythrocyte, leukocyte, and platelet production, providing direct evidence for dose selection and regimen optimization.

Hepatorenal Function

Drug-induced liver injury (DILI) and nephrotoxicity are major causes of drug development failure. Combined serum biochemistry (ALT, AST, BUN, CREA) and urinalysis provide critical data for evaluating hepatic and renal safety.

CNS Safety

BBB-penetrant drugs, including small molecule targeted agents and oncolytic viruses, may cause CNS adverse effects. CSF biochemical and cytological analysis provides key data for assessing CNS penetrability and neurotoxicity.

Toxicology Profiling

Integration of CBC, serum biochemistry, urinalysis, coagulation, and specialized fluid analyses forms a comprehensive clinical pathology framework for preclinical toxicology studies, delivering critical data for regulatory submissions.

Alfa Cytology offers flexible biochemical and body fluid analysis services covering CBC, serum biochemistry, urinalysis, coagulation panel, and CSF, pleural/peritoneal fluid, synovial fluid, and fecal samples. Our solutions support chemotherapy, targeted therapy, ADCs, and immunotherapy, with customizable options from single assays to integrated packages. Please don't hesitate to contact us to learn how our services can accelerate your oncology drug development.

For research use only.